Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 17, Number 9—September 2011

CME ACTIVITY

Mycobacterium chelonae-abscessus Complex Associated with Sinopulmonary Disease, Northeastern USA

Keith E. Simmon1Comments to Author , Barbara A. Brown-Elliott1, Perry G. Ridge, Jacob D. Durtschi, Linda Bridge Mann, E. Susan Slechta, Arnold G. Steigerwalt, Benjamin D. Moser, Anne M. Whitney, June M. Brown, Karl V. Voelkerding, Karin L. McGowan, Anne F. Reilly, Thomas J. Kirn, W. Ray Butler, Paul H. Edelstein, Richard J. Wallace, and Cathy A. Petti
Author affiliations: Author affiliations: Associated Regional and University Pathologists Institute for Clinical and Experimental Pathology, Salt Lake City, Utah, USA (K.E. Simmon, P.G. Ridge, J.D. Durtschi, E.S. Slechta, K.V. Voelkerding, C.A. Petti); University of Texas Health Science Center, Tyler, Texas, USA (B.A. Brown-Elliott, L.B. Mann, R.J. Wallace, Jr.); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (A.G. Steigerwalt, B.D. Moser, A.M. Whitney, J.M. Brown, W.R. Butler); University of Utah School of Medicine, Salt Lake City, Utah, USA (K.V. Voelkerding, C.A. Petti); University of Pennsylvania School of Medicine at Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA (K.F. McGowan, A.F. Reilly); Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA (T.J. Kirn); University of Pennsylvania Medical Center, Philadelphia (P.H. Edelstein)

Main Article

Table A1

Antimicrobial drug susceptibility profiles of CV isolates compared with Mycobacterium chelonae, M. massiliense, and M. abscessus isolates*

Antimicrobial drug
M. abscessus, n = 41

M. massiliense, n = 5

M. chelonae, n = 58

CV, n = 25
Range
S, %
I, %
R, %
Range
S, %
I, %
R, %
Range
S, %
I , %
R, %
Range
S, %
I, %
R, %
Amikacin 8−32 73.2 26.8 0.0 8−32 60.0 40.0 0.0 8−>256 32.8 51.7 15.5 8−32 92.0 8.0 0.0
Cefoxitin 16−64 9.8 90.2 0.0 16−32 40.0 60.0 0.0 64−> 512 0.0 1.7 98.3 16−64 12.0 88.0 0.0
Ciprofloxacin† <0.25−>32 2.4 0.0 97.6 4−16 0.0 0.0 100.0 1−>32 8.6 17.2 74.2 <0.25−8 60.0 20.0 20.0
Clarithromycin <0.12−4 97.6 2.4 0.0 <0.12 100.0 0.0 0.0 <0.12−>64 98.3 0.0 2.4 <0.12−1 100.0 0.0 0.0
Gatifloxacin‡ <0.5−>16 2.4 14.6 83.0 4−16 0.0 20.0 80.0 1−>16 31.0 44.8 24.2 <0.5−4§ 80.0 20.0 0.0
Imipenem 1−32 14.6 53.6 31.8 8 0.0 100.0 0.0 <0.5−64 10.3 34.5 55.2 1−64 16.0 44.0 40.0
Linezolid 4−32 43.9 36.6 19.5 8−16 20.0 60.0 20.0 <0.1−32 81.0 13.8 5.2 1−32 72.0 24.0 4.0
Minocycline 8−64 0.0 4.9 95.1 64 0.0 0.0 100.0 <0.5−>64 15.5 3.5 81.0 <0.5−16¶ 90.9 9.1 0.0
Tobramycin 4−32 2.4 22.0 75.6 8−32 0.0 0.0 100.0 1−>128 98.3 0.0 1.7 4−16# 62.5 29.2 8.3
Trimethoprim/ sulfamethoxazole 4/76−>16/304 0.0 100.0 >16/304 0.0 100.0 <0.5/9.5−>16/304 5.2 94.8 1/9−>16/304 8.0 92.0

*CV, M. chelonae variant; S, susceptible; I, intermediate; R, resistant; –, not applicable. One CV isolate did not grow on solid media.
†Read at 3 days
‡No CLSI breakpoint recommendation has been proposed for gatifloxacin. Manufacturer recommendation of 4 used as the intermediate breakpoint.
§10 isolates tested.
¶22 isolates tested.
#24 isolates tested.

Main Article

1These authors contributed equally to this article.

TOP